ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.
On March 13, 2017, Aralez Pharmaceuticals Inc., a company formed
under the laws of the Province of British Columbia, Canada (the
Company), issued a press release announcing its results of
operations for the quarter and full-year ended December 31, 2016.
The full text of such press release is furnished as Exhibit99.1
to this report and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosures.
As previously announced, the Company will conduct a conference
call today, Monday, March 13, 2017 at 9:00 a.m.ET, to discuss its
2016 fourth quarter financial results and recent highlights. The
presentation slides to be used during the call will be available
on the Investors section of the Companys website
(http://www.aralez.com) under the Presentations Webcasts tab
beginning at 9:00 a.m.ET on Monday, March 13, 2017. A question
and answer session will follow the presentation. The conference
call and the presentation slides will be simultaneously webcast
on the Investors section of the Companys website under the
Presentations Webcasts tab beginning at 9:00 a.m.ET on Monday,
March 13, 2017, and will remain available for future review for
two weeks after the event. The information contained in, or that
can be accessed through the Companys website, is not a part of
this filing.
Item9.01. Financial Statements and Exhibits
(d)List of Exhibits
|
EXHIBIT NO. |
DESCRIPTION |
|
99.1 |
Press Release, dated March 13, 2017, issued by Aralez |
– 2-
About ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ)
Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID). ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Recent Trading Information
ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) closed its last trading session down -0.01 at 3.53 with 1,129,105 shares trading hands.
